CoChat
Sign Up
Cited by 28Bariatric Surgery and OutcomesLiver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

Open access
Nguyen, Vi, Li, Jiawei, Gan, Jaslyn, Cordero, Paul, Ray, Shuvra, Solis-Cuevas, Alessandro, Khatib, Mai, Oben, Jude A.·2017·Canadian Journal of Gastroenterology and Hepatology
DOI 10.1155/2017/4697194PMC PMC5758844
Open this paper in CoChat — free accountOpen PDF

Abstract

Background. The incidence of nonalcoholic fatty liver disease (NAFLD) continues to parallel the rise in obesity rates. Endobariatric devices such as the intragastric balloon (IGB) may provide an alternative treatment option.Methods. Outcomes following IGB treatment in 135 patients with obesity and NAFLD (mean baseline weight 117.9 kg; BMI 41.7 kg/m 2; HOMA-IR 3.6) were retrospectively examined. Clinical, anthropometric, and biochemical changes were analysed at six months and after consecutive treatment with two and three serial IGBs.Results. After six months, significant changes were seen with weight and BMI (mean reductions of 11.3 kg and 4.1 kg/m 2, resp.,p<0.01for both). Significant improvements were also seen with ALT, GGT, and HOMA-IR, with all changes corresponding with weight loss. Forty-eight patients received two IGBs, and 20 were treated with three serial IGBs. The greatest amount of total weight loss was observed after the first 6 months (mean weight lost 7.4 kg, versus 3.6 kg and 1.9 kg with two and three IGBs, resp.).Conclusions. IGB therapy is an effective, alternative nonsurgical means for weight loss in the management of obesity and NAFLD over the short term, with greatest outcomes observed after six months. Improvements in insulin resistance and hepatic transaminases correlated with weight change.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2017/4697194

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IGB therapy reduces GGT from 57% to 34%.

    “another study reported reductions in ALT and GGT from 42% to 22% and 57% to 34%, respectively, signifying enhanced liver function particularly in metabolically compromised patients [76].”

    From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [76]

    The Results (§3.4) report a decrease from 57% to 34% in the prevalence of elevated GGT after six months of IGB therapy. These percentages are not GGT levels, and the reported significant improvement was limited to patients with elevated HOMA-IR at baseline. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • IGB therapy reduces ALT from 42% to 22%.

    “another study reported reductions in ALT and GGT from 42% to 22% and 57% to 34%, respectively, signifying enhanced liver function particularly in metabolically compromised patients [76].”

    From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [76]

    The Results (§3.4) report that, after six months of IGB therapy, the prevalence of elevated ALT fell from 42% to 22%. Those percentages describe the proportion of patients with elevated ALT, not a reduction in ALT levels themselves; significant ALT improvement was observed only in patients with elevated HOMA-IR at baseline. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • IGB reduces ALT by 20.3-38%.

    “Other procedures showed variable ALT reductions: IGB (20.3–38%) [74,76], DMR (29.3%) [94], and ESG (16%) [83].”

    From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [76]

    Results §3.4 reports improved serum ALT after six months of IGB therapy, but says the improvement was significant only among patients with elevated HOMA-IR at baseline. It does not report a 20.3–38% reduction in ALT; the 42% to 22% figures describe the prevalence of elevated ALT, not the amount by which ALT fell. No page number is available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • IGB therapy enhances liver function particularly in metabolically compromised patients.

    “another study reported reductions in ALT and GGT from 42% to 22% and 57% to 34%, respectively, signifying enhanced liver function particularly in metabolically compromised patients [76].”

    From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [76]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. 10.1053/j.gastro.2011.06.061 · DOI
  2. 10.1016/j.bpg.2014.07.008 · DOI
  3. 10.3390/ijms17060947 · DOI
  4. 10.1111/jpn.12283 · DOI
  5. 10.1097/MCO.0000000000000179 · DOI
  6. 10.1089/met.2015.0095 · DOI
  7. 10.1016/s0140-6736(14)61316-7 · DOI
  8. 10.1038/nrdp.2017.34 · DOI
  9. 10.1053/j.gastro.2010.09.038 · DOI
  10. 10.1002/hep.21327 · DOI · Paper page
  11. 10.1053/j.gastro.2005.04.014 · DOI · Paper page
  12. 10.1056/NEJMoa021423 · DOI · Paper page
  13. 10.1136/bmj.d6891 · DOI
  14. 2003, American Journal of Clinical Nutrition, 78, 1079, 10.1093/ajcn/78.6.1079 · DOI
  15. 10.1001/jama.2014.5988 · DOI · Paper page
  16. 10.1007/s11695-007-9331-8 · DOI
  17. 10.1007/s00592-013-0516-4 · DOI
  18. 10.1016/j.gie.2009.06.036 · DOI · Paper page
  19. 10.4137/IMI.S31451 · DOI
  20. 10.1097/SLE.0000000000000440 · DOI
  21. 10.4324/9780203987858 · DOI
  22. 10.1136/gutjnl-2013-304490 · DOI
  23. 10.1186/1756-0500-7-242 · DOI
  24. 10.1007/s11695-012-0829-3 · DOI
  25. 10.1038/sj.ijo.0803094 · DOI
  26. 10.1016/S0016-5107(04)02406-X · DOI
  27. 10.1002/hep.24127 · DOI · Paper page
  28. 10.1016/j.gie.2012.05.023 · DOI
  29. 10.1007/s11695-010-0231-y · DOI
  30. 10.1007/s11695-007-9383-9 · DOI
  31. 10.5114/wiitm.2015.55748 · DOI

Cited by

Sorted by citations

Authors
Nguyen, V., Li, J., Gan, J., Cordero, P., Ray, S., Solis-Cuevas, A., Khatib, M., & Oben, J. A.
Affiliations
  • Guy's Hospital (GB)
  • The Royal Free Hospital (GB)
  • Institute for Liver and Digestive Health, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK
  • University College London (GB)
Corresponding author
Oben, Jude A.
ORCID
Venue
Canadian Journal of Gastroenterology and Hepatology
Publisher
Wiley
Published
2017
Volume
2017
Pages
1-8
ISSN
  • 2291-2789 (ISSN-L)
  • 2291-2797
DOI
10.1155/2017/4697194
PMC
PMC5758844
OpenAlex
W2776181098
Cited by
28
References
6
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 4 · 2019: 4
FWCI
2.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Obesity Action Campaign
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
intragastric balloon, obesity, non-alcoholic fatty liver disease, weight loss, insulin resistance, hepatic transaminases
MeSH terms
Adult, Female, Humans, Liver, Liver Function Tests, Male, Middle Aged, Obesity, Retrospective Studies, Gastric Balloon, Treatment Outcome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review